Clinical Trials Directory

We are doing this study to find out if 2 experimental treatments for high risk prostate cancer are effective compared to the usual treatments. For people with this form of cancer who also have a low gene risk score, we want to know if a short course of hormone treatment is as effective as the usual 24-month treatment. For people with a high gene risk score who will receive radiation, we want to know if adding a drug called apalutamide (study drug) to the usual treatment helps to slow the cancer's spread.

We are doing this study to learn more about using Decipher risk scores to guide how we treat cancer. During the study, we will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading. This is called the Decipher risk score. This study will use Decipher risk scores as a guide for intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. We also want to know how well an investigational drug called darolutamide (the study drug) works for people with high risk scores.

We are doing this study to find out if adding radiation therapy has any positive benefit when it is added to the usual treatment regimen for this form of cancer.

We are doing this study to learn if taking Paclitaxel and Carboplatin, folllowed by Letrozole or taking Letrozole alone is best to lower the chance of ovarian or peritoneal cancer spreading.

We are doing this study to see if radiation and chemotherapy can be done instead of an extensive surgical removal of the groin lymph nodes for patients with vulvar cancer whose disease has spread to the sentinel node. We are doing this study because we want to find out if this approach is better or worse than the usual approach for vulvar cancer.

We are doing this study to find out if the study drugs nivolumab and ipilimumab are a safe and effective option for people who have endometrial cancer that does not respond to standard treatment and/or has spread to other parts of the body. We want to compare the results of using these 2 drugs together versus using nivolumab alone.

We are doing this study to find out if adding drugs that target HER2 proteins to the standard therapy for endometrial cancer can improve the chance of remission or lower the risk that the cancer comes back after treatment. We want to know how well patients do on the standard treatment compared to two experimental study regimens.

We are doing this study to find out if stereotactic body radiation therapy (SBRT) might be beneficial for people with non-small cell lung cancer (NSCLC). We want to compare the outcomes between the standard treatment for NSCLC and the standard treatment with the addition of SBRT.